Evercore ISI reaffirmed their buy rating on shares of Regenxbio (NASDAQ:RGNX) in a research note released on Monday, AnalystRatings.com reports. They currently have a $65.00 price target on the biotechnology company’s stock.
A number of other analysts have also recently commented on RGNX. Svb Leerink raised Regenxbio from an underperform rating to a market perform rating and lowered their price target for the stock from $38.00 to $37.00 in a research report on Tuesday, August 20th. ValuEngine upgraded Regenxbio from a buy rating to a strong-buy rating in a research note on Thursday, August 1st. Morgan Stanley reduced their price objective on Regenxbio from $85.00 to $59.00 and set an overweight rating for the company in a research note on Friday, October 11th. BidaskClub upgraded Regenxbio from a sell rating to a hold rating in a research note on Thursday, October 3rd. Finally, Chardan Capital set a $150.00 price objective on Regenxbio and gave the company a buy rating in a research note on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $72.38.
RGNX traded down $0.28 on Monday, reaching $36.32. 356,500 shares of the stock were exchanged, compared to its average volume of 559,129. The company’s 50-day moving average price is $37.56 and its 200 day moving average price is $42.40. Regenxbio has a fifty-two week low of $30.38 and a fifty-two week high of $65.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.49 and a quick ratio of 11.49. The firm has a market capitalization of $1.42 billion, a PE ratio of 15.26 and a beta of 0.81.
Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.03). Regenxbio had a negative return on equity of 18.74% and a negative net margin of 99.57%. The firm had revenue of $14.70 million for the quarter, compared to analyst estimates of $7.46 million. During the same period in the prior year, the firm posted ($0.56) EPS. The business’s revenue was up 177.0% compared to the same quarter last year. As a group, equities analysts forecast that Regenxbio will post -2.8 earnings per share for the current fiscal year.
In other Regenxbio news, SVP Patrick J. Christmas sold 5,486 shares of Regenxbio stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $42.00, for a total transaction of $230,412.00. Following the completion of the transaction, the senior vice president now owns 8,058 shares in the company, valued at approximately $338,436. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kenneth T. Mills sold 15,000 shares of Regenxbio stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $37.55, for a total value of $563,250.00. Following the transaction, the insider now owns 261,000 shares of the company’s stock, valued at approximately $9,800,550. The disclosure for this sale can be found here. Insiders have sold a total of 30,486 shares of company stock valued at $1,191,162 in the last quarter. Company insiders own 13.80% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund increased its position in shares of Regenxbio by 4.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 12,158 shares of the biotechnology company’s stock valued at $625,000 after purchasing an additional 498 shares during the last quarter. NEXT Financial Group Inc bought a new position in shares of Regenxbio during the 2nd quarter worth $69,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Regenxbio during the 2nd quarter worth $290,000. Fox Run Management L.L.C. bought a new position in shares of Regenxbio during the 2nd quarter worth $269,000. Finally, Arizona State Retirement System grew its stake in shares of Regenxbio by 1.2% during the 2nd quarter. Arizona State Retirement System now owns 47,739 shares of the biotechnology company’s stock worth $2,452,000 after acquiring an additional 547 shares during the period. Institutional investors and hedge funds own 79.54% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Featured Story: Why Invest in Dividend Achievers?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.